Viking Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VKTX in the last 30 days.
See all $VKTX insider activity →Truist analyst Gregory Renza reduced Viking Therapeutics' price target to $85 from $87, maintaining a Buy rating. The firm expects biotech sector strength but cautions about valuation, macroeconomic factors, and policy risks. Truist prefers companies with clear revenue growth and differentiated profiles.
Viking Therapeutics (VKTX) began Part 2 of a maintenance dosing study for VK2735, its obesity treatment. The trial will test oral and subcutaneous dosing regimens in 195 adults with obesity. Part 1 showed positive results. Part 2 results are expected in 2027. Viking is also running two Phase 3 studies, VANQUISH-1 and VANQUISH-2, for subcutaneous VK2735.
Viking Therapeutics (VKTX) rose 24% in September after positive Phase 1 data for VK2735, a weight-loss drug, but ended the month down 3.18% due to a $575M financing. Longeveron (LGVN) fell 64% after its stem cell therapy failed a Phase 2b trial, triggering a strategic review. The broader biotech sector declined 3.5% in September.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning VKTX (Viking Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 7 neutral, and 3 bearish.
Recent VKTX coverage spans financial news, technology and corporate actions.
Analyst price‑target cut suggests modest downside pressure.
The study could expand VKTX's pipeline and market potential if oral dosing shows safety and efficacy.
Positive trial data supports upside, but large dilutive financing creates pressure.
The trial readout and capital raise could lift the stock if investors view the data positively, but current valuation appears stretched.
The new capital gives Viking Therapeutics runway to advance its obesity program, but the equity issuance adds dilution risk.
AlphAI scores every news story that mentions VKTX with an AI model for sentiment and relevance, and aggregates insider trades from Viking Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Truist analyst Gregory Renza reduced Viking Therapeutics' price target to $85 from $87, maintaining a Buy rating. The firm expects biotech sector strength but cautions about valuation, macroeconomic factors, and policy risks. Truist prefers companies with clear revenue growth and differentiated profiles.
1 min readViking Therapeutics (VKTX) began Part 2 of a maintenance dosing study for VK2735, its obesity treatment. The trial will test oral and subcutaneous dosing regimens in 195 adults with obesity. Part 1 showed positive results. Part 2 results are expected in 2027. Viking is also running two Phase 3 studies, VANQUISH-1 and VANQUISH-2, for subcutaneous VK2735.
2 min readViking Therapeutics (VKTX) rose 24% in September after positive Phase 1 data for VK2735, a weight-loss drug, but ended the month down 3.18% due to a $575M financing. Longeveron (LGVN) fell 64% after its stem cell therapy failed a Phase 2b trial, triggering a strategic review. The broader biotech sector declined 3.5% in September.
3 min readViking Therapeutics (VKTX) reported positive top-line data for its VK2735 obesity maintenance study and raised over US$500m. Despite this, the share price has declined 15.8% in 7 days and 22.7% in 90 days, trading at US$29.94. The company's P/B ratio of 8.6x is significantly higher than its peers, suggesting high expectations for future value creation. A DCF model estimates the stock's value at US$7.34, indicating potential overvaluation.
2 min readViking Therapeutics (VKTX) raised $500M via equity and convertible notes after positive obesity drug (VK2735) data. The funds support trials and pipeline expansion. Analysts project $118.5M revenue and $12.9M earnings by 2029, with 210% upside potential. Dilution and execution risks remain.
2 min readViking Therapeutics (VKTX) stock rose 8.4% after positive drug trial results, but fell below its $35 offering price. The company raised $575M via stock and convertible notes, diluting shares by 7.2%. Earnings per share per dollar invested dropped 14.4%.
2 min readViking Therapeutics (VKTX) shares fell 6.1% due to dilution concerns from a $575M equity and convertible note offering, despite positive obesity-drug data. The company sold 9M shares at $35 each, and insiders sold shares recently. Analysts' price targets range up to $125.
2 min readViking Therapeutics (VKTX) stock surged 36% after positive clinical trial results for its weight-loss drug, VK2735. Patients maintained significant weight loss with less frequent dosing. The company plans further studies, but risks include share dilution and competitive market. Investors should consider potential upside and downside.
3 min readEli Lilly (LLY) leads the weight-loss market but faces competition from Viking Therapeutics (VKTX). Viking's clinical trial showed promising weight-loss results for VK2735, but Eli Lilly's stock barely moved due to uncertainties and its own maintenance strategies. Eli Lilly's diversified pipeline and strong financials make it attractive, while Viking offers potential upside but with higher risk.
3 min readVKTX stock declined over three days despite positive analyst comments on its weight loss drug data. Analysts raised price targets, implying potential upsides of 163% to 263%. Retail traders on Stocktwits expressed bullish sentiment, citing the company's funding and potential buyout. VKTX has gained 29% year-to-date.
1 min read
